life science investing LUPKYNIS® Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone
life science investing Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees
life science investing Aurinia Pharmaceuticals Announces Kidney Biopsies Sub-study Data from the LUPKYNIS® AURORA 2 Clinical Trial Presented at Congress of Clinical Rheumatology East Conference
life science investing Aurinia Pharmaceuticals Reports First Quarter 2023 Financial and Operational Results
life science investing Aurinia Pharmaceuticals Announces NICE Recommendation of LUPKYNIS® For Adults with Active Lupus Nephritis
life science investing ISS Joins Glass Lewis in Recommending Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual General Meeting
life science investing Glass Lewis Recommends Aurinia Shareholders Vote "FOR" ALL Company Director Nominees at 2023 Annual Meeting
life science investing Toni Braxton and Aurinia Want People with Lupus Nephritis to Get Uncomfortable to Protect their Kidneys
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis
Skyharbour's Partner Company Mustang Energy Commences Field Program at 914W Uranium Project Located in the Athabasca Basin, Saskatchewan
Bold Ventures Announces Increase and Extension of Non-Brokered Private Placement and Closing of Third Tranche, and Signs Agreement with Investor News Network
